Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
182 hedge funds and large institutions have $679M invested in Eagle Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 56 increasing their positions, 61 reducing their positions, and 20 closing their positions.
20% more capital invested
Capital invested by funds: $567M → $679M (+$112M)
0% more funds holding
Funds holding: 182 → 182 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 20
8% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 61
47% less call options, than puts
Call options by funds: $4.74M | Put options by funds: $9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$7.42M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.83M |
| 3 |
SGCIA
Smith Graham & Co Investment Advisors
Houston,
Texas
|
+$3.95M |
| 4 |
SCM
Sio Capital Management
New York
|
+$3.77M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WG
Winton Group
London,
United Kingdom
|
-$9.55M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.76M |
| 3 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$6.5M |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
-$5.19M |
| 5 |
Citigroup
New York
|
-$4.72M |
EGRX Hedge Fund Activity: Q1 2019 in Review
182 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2019, worth a combined $679M — up 20% from $567M a quarter earlier.
Fund positioning in EGRX was balanced in Q1 2019: 20 funds opened new positions, 20 closed out, 56 added to existing stakes and 61 trimmed.
The largest buyer was LSV Asset Management, adding an estimated $7.42M. The largest seller was Winton Group, exiting entirely with an estimated $9.55M sold.
- 182 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $679M of Eagle Pharmaceuticals, Inc. stock for Q1 2019, up 20% quarter-over-quarter.
- 20 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2019 and 20 closed out, a net change of 0 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2019 was LSV Asset Management, an estimated $7.42M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q1 2019 was Winton Group, an estimated $9.55M sold.
Based on aggregated 13F filings for Q1 2019.